CAR T-cell therapy is a treatment that uses a patient’s own T cells, genetically reprograms them in a lab to recognize ...

A new research paper was published in Volume 17 of Oncotarget on April 28, 2026, titled "Targeted therapeutics and U.S. population-level mortality trends in multiple myeloma: A SEER-based analysis ...

Bispecific antibodies are currently approved as late-line therapy, but they are moving up to earlier lines “as they prove ...

Topline data from the MagnetisMM-5 study demonstrate the superiority of elranatamab monotherapy over daratumumab plus pomalidomide and dexamethasone in double-class exposed multiple myeloma patients.

Although patients with the same cancer diagnosis may respond very differently to treatment, clinicians still have limited ...

Nearly three years after the FDA approved Pfizer's bispecific antibody Elrexfio as a late-line treatment for patients with ...

CAR T, bispecific antibodies, and oral CELMoDs—expand options, protect QOL, and raise hopes of cure, notes Asya Nina ...

Right now, CELMoDs are being studied in patients whose cancer has returned after prior treatment, but their role could expand ...

CAR-T and bispecifics in multiple myeloma are reshaping sequencing, enabling earlier use, but access and standardization ...

We are entering an era where "cure," specifically a functional cure, is no longer a forbidden word in the myeloma community.

Chemotherapy is a treatment that uses strong medicines to kill cancer cells or slow their growth. It is a type of systemic therapy, which means it travels through the bloodstream to reach and attack ...

A healthcare provider shares her journey with multiple myeloma, discussing the physical, emotional and financial challenges ...